Financial Performance - The company's operating revenue for Q1 2024 was RMB 324,809,103.67, representing a decrease of 12.07% compared to the same period last year[5]. - The net profit attributable to shareholders of the listed company was a loss of RMB 272,222,474.99, a decline of 244.98% year-on-year[5]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was a loss of RMB 280,666,741.34, down 251.92% year-on-year[5]. - The weighted average return on net assets was -3.35%, a decrease of 5.62 percentage points compared to the previous year[5]. - The net profit attributable to shareholders, excluding non-recurring gains and losses, was -251.92 million RMB, primarily due to a decrease in net profit from laboratory services and losses from changes in the fair value of biological assets[31]. - Basic and diluted earnings per share were both -244.00 RMB[31]. - Total revenue for Q1 2024 was RMB 324,809,103.67, a decrease of 12.06% compared to RMB 369,386,010.95 in Q1 2023[44]. - Operating profit for Q1 2024 was RMB -293,008,274.73, compared to RMB 214,369,686.98 in Q1 2023, indicating a significant decline[48]. - Net profit for Q1 2024 was RMB -273,363,603.07, a decrease from a net profit of RMB 187,710,078.62 in Q1 2023[48]. - The total comprehensive income for Q1 2024 was -$272.50 million, compared to $183.31 million in Q1 2023, reflecting a substantial decrease in overall performance[50]. - The basic and diluted earnings per share for Q1 2024 were both -$0.36, down from $0.25 in Q1 2023, highlighting a negative shift in profitability[50]. Assets and Liabilities - Total assets at the end of the reporting period were RMB 9,733,254,487.30, a decrease of 2.93% from the end of the previous year[8]. - The equity attributable to shareholders of the listed company was RMB 7,993,144,600.58, down 3.46% from the end of the previous year[8]. - Non-current assets totaled RMB 2,762,090,308.72, down from RMB 2,905,192,290.36 in the previous period[44]. - Total assets decreased to RMB 9,733,254,487.30 from RMB 10,027,159,630.47[44]. - Total liabilities amounted to RMB 1,739,526,324.07, slightly down from RMB 1,746,119,215.39[44]. - Deferred income tax liabilities were RMB 129,567,321.33, down from RMB 162,342,125.15[44]. Cash Flow - The net cash flow from operating activities was RMB 119,953,519.31, with no applicable year-on-year comparison[5]. - Cash inflows from operating activities in Q1 2024 totaled $492.59 million, a decrease of 22.4% from $635.83 million in Q1 2023[52]. - The net cash flow from operating activities for Q1 2024 was $119.95 million, a significant improvement compared to a net outflow of -$13.67 million in Q1 2023[52]. - Cash outflows for investing activities in Q1 2024 amounted to $179.02 million, compared to $115.88 million in Q1 2023, indicating increased investment expenditures[58]. - The net cash flow from investing activities for Q1 2024 was -$67.56 million, contrasting with a positive cash flow of $106.48 million in Q1 2023[58]. - The cash and cash equivalents at the end of Q1 2024 were $2.87 billion, a slight decrease from $2.96 billion at the end of Q1 2023[58]. - The company reported cash inflows from other operating activities of $18.49 million in Q1 2024, down from $21.31 million in Q1 2023[52]. - The company experienced a foreign exchange loss of $2.80 million on cash and cash equivalents in Q1 2024, compared to a loss of $6.27 million in Q1 2023[58]. Operational Highlights - New orders signed during the reporting period were approximately 400 million RMB, with a year-on-year increase of about 20%, resulting in a total backlog of approximately 3.38 billion RMB[34]. - The laboratory service business contributed a net loss of RMB 21,043,700.00, a decline of 130.01% year-on-year[24]. - Research and development expenses for Q1 2024 were RMB 22,967,298.39, a decrease from RMB 27,611,585.58 in Q1 2023[48]. - The company has ongoing research and development efforts, although specific new products or technologies were not detailed in the report[34]. Shareholder Information - The top ten shareholders held a combined 74.29% of the shares, with the largest shareholder owning 22.29%[32].

Financial Performance - JOINN Laboratories reported a revenue increase of 25% year-over-year, reaching RMB 1.5 billion in the latest fiscal year[36]. - The company's revenue for the year ended December 31, 2023, was RMB 2,376,487 thousand, representing an increase from RMB 2,267,971 thousand in 2022, which is a growth of approximately 4.8%[43]. - The total revenue for the year ended December 31, 2023, was RMB 2,376.5 million, representing a 4.8% increase from RMB 2,268.0 million for the year ended December 31, 2022[59]. - The company achieved a revenue of RMB 2.376 billion in 2023, with a net profit from laboratory services of RMB 473 million[45]. - The company's net profit for the year decreased by 63.5% to RMB 391.6 million from RMB 1,073.2 million in the previous year, with a net profit margin dropping from 47.3% to 16.5%[65]. - Earnings per share (EPS) for 2023 was RMB 0.53, down from RMB 1.44 in 2022, indicating a decline in profitability per share[43]. Market Expansion and Strategy - Future outlook indicates a projected revenue growth of 20% for the next fiscal year, driven by new product launches and market expansion strategies[36]. - The company plans to enter two new international markets by the end of 2024, targeting a 15% market share in each[36]. - The company is focusing on market expansion strategies, particularly in the biopharmaceutical sector, to enhance its competitive position[43]. - The company is actively seeking strategic investment opportunities to enhance product development, portfolio, channel expansion, or cost control[75]. - The company plans to enhance its pharmacology and toxicology research capabilities, improve project management efficiency, and ensure compliance with GLP standards[77]. Research and Development - JOINN is investing RMB 200 million in R&D for new technologies aimed at enhancing drug testing capabilities[36]. - The company is investing in research and development to innovate new therapies and improve existing product lines, which is critical for long-term sustainability[43]. - Research and development expenses increased by 24.2% to RMB 96.9 million, driven by continuous investment in R&D projects[64]. - The company has developed and optimized 11 new ophthalmic disease models to enhance drug evaluation capabilities[50]. - The company has developed an AI-based automated behavioral assessment system for CNS diseases, achieving 100% accuracy in drug delivery techniques using MRI-guided stereotactic injection[52]. Operational Efficiency - The company aims to increase operational efficiency by 10% through the implementation of advanced data analytics tools[36]. - The company aims to improve operational efficiency to counteract the declining gross profit margin observed in recent years[43]. - The company has set a goal to reduce operational costs by 5% through strategic partnerships and supply chain optimization[36]. Sustainability Initiatives - JOINN's commitment to sustainability includes a target to reduce carbon emissions by 20% over the next three years[36]. - The management team emphasized a focus on sustainability initiatives, aiming for a 30% reduction in carbon emissions by 2025[101]. Client and Supplier Relationships - The company served approximately 850 clients, including major pharmaceutical and biotechnology companies, as of December 31, 2023[169]. - The company maintains stable relationships with major suppliers, primarily located in China, and has not faced any significant procurement difficulties for general laboratory consumables or equipment during the reporting period[172]. - The company has established long-term procurement contracts with suppliers of non-human primate experimental models, ensuring sufficient supply at reasonable prices without any adverse operational impacts reported[173]. Employee and Management - JOINN's employee stock ownership plan has seen participation rise to 75% among eligible employees, fostering greater alignment with company performance[36]. - The company has a professional service team of 2,510 members as of December 31, 2023[46]. - The company has established long-term incentive mechanisms to attract and retain talent, promoting sustainable and healthy development[126]. Corporate Governance - The board consists of 9 members, including 5 executive directors and 4 independent non-executive directors[198]. - The company has adopted the corporate governance code as per Appendix C1 of the listing rules[194]. - The board is responsible for ensuring that the company operates in the best interests of its shareholders[198]. Financial Position - The total assets decreased to RMB 10,027,159 thousand in 2023 from RMB 10,364,216 thousand in 2022, representing a decline of approximately 3.2%[44]. - Total liabilities decreased to RMB 1,746,118 thousand in 2023 from RMB 2,173,350 thousand in 2022, a reduction of about 19.6%[44]. - The company's net assets increased to RMB 8,281,041 thousand in 2023, up from RMB 8,190,866 thousand in 2022, reflecting a growth of approximately 1.1%[44]. Challenges and Risks - The company faces risks from fluctuating international economic conditions and potential impacts on international business revenue due to geopolitical instability[84]. - Intense market competition in the non-clinical CRO industry requires the company to maintain its core competitive advantages and complete fundraising projects promptly to avoid profitability challenges[87]. - The company must keep pace with technological innovations in the pharmaceutical research sector to maintain its industry leadership; failure to adapt could reduce client demand for services[89].

北京昭衍新药研究中心股份有限公司 关于与专业投资机构合作参与投资设立产业基金暨关联交 易的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 2024 年 2 月 5 日，北京昭衍新药研究中心股份有限公司（以下简称"公司" 或"昭衍新药"）召开第四届董事会第六次会议及 2024 年第一次独立董事专门会 议，审议通过了《关于公司与专业投资机构合作参与投资设立产业基金暨关联交 易的议案》，同意公司与无锡国联产业投资私募基金管理有限公司、北京宏儒和 愉投资管理有限公司、无锡市创新投资集团有限公司及江苏原力产业投资有限公 司签署《无锡金易赋新生物医药创业投资合伙企业（有限合伙）有限合伙协议》 （以下简称"《合伙协议》"），共同出资发起设立无锡金易赋新生物医药创业 投资合伙企业（有限合伙）。基金认缴出资总额为 10 亿元人民币，公司作为有 限合伙人认缴出资 3 亿元人民币，占有限合伙 30%份额，出资方式为货币出资。 公司关联董事已对该议案回避表决，并已在提交董事会审议前经独立董事专门会 议审议通过。 具 体 信 息 详 见 公 ...

董事會召開日期 北京昭衍新藥研究中心股份有限公司（「本公司」及其附屬公司統稱為「本集團」） 之董事會（「董事會」）兹通告謹定於2024年4月29日（星 期 一）舉 行 董 事 會 會 議，以 考慮及通過（其 中 包 括）本集團截至2024年3月31日止三個月之第一季度業績及 其 發 佈。 承董事會命 北京昭衍新藥研究中心股份有限公司 主 席 馮宇霞 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 對 因 本 公 告 全部或任何部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責 任。 JOINN LABORATORIES (CHINA) CO., LTD. 北京昭衍新藥研究中心股份有限公司 （於 中 華 人 民 共 和 國 註 冊 成 立 的 股 份 有 限 公 司） （股 份 代 號：6127） 中 國，北 京 2024年4月16日 於 本 公 告 日 期，本 公 司 董 事 會 包 括 主 席 兼 執 行 董 事 馮 宇 霞 女 士、執 行 董 事 左 從 林 先 生、高 大 鵬 ...

证券研究报告 | 2024年04月15日 2023 全年收入基本持平，国际化战略成效显现 | --- | --- | --- | --- | --- | --- | |----------------------------------------|-------|--------|-------|----------------------------------|-------| | 盈利预测和财务指标 | 2022 | 2023 | 2024E | 2025E | 2026E | | 营业收入(百万元) | 2,268 | 2,376 | 2,389 | 2,652 | 2,948 | | (+/-%) | 49.5% | 4.8% | 0.5% | 11.0% | 11.1% | | 净利润(百万元) | 1074 | 397 | 404 | 546 | 604 | | (+/-%) | 92.7% | -63.0% | 1.8% | 35.0% | 10.6% | | 每股收益（元） | 1.43 | 0.53 | 0.54 | 0.73 | 0.80 | | EBIT Margin | 30.6% ...

公司于 2021 年 2 月 4 日召开了第三届董事会第二十五次会议，审议通过了 《批准关联交易的议案》，其中关联董事均予以回避表决，且该日常关联交易已 经独立董事事前认可并发表独立意见。 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 北京昭衍新药研究中心股份有限公司（以下简称"本公司"或"昭衍新药"） 分别于 2021 年 2 月 5 日及 2024 年 2 月 6 日披露了《北京昭衍新药研究中心股份 有限公司日常持续性关联交易的公告》（公告编号：2021-022、2024-004），披露 了关于公司及其子公司与关联方生仝智能科技（北京）有限公司（下称"生仝智 能"）进行日常持续性关联交易的内容。现将公司与生仝智能的关联关系进一步 补充说明如下： 一、与上市公司的关联关系 本公司的实际控制人冯宇霞、周志文夫妇与生仝智能的董事长兼实际控制人 周冯源先生为直系亲属关系，且周志文先生在生仝智能担任董事职务，符合《上 海证券交易所股票上市规则》6.3.3 的相关规定，因此生仝智能构成公司的关联 法人。 二、关联交易履行的审议程序和 ...

研究 可更新 | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | |----------------------|-----------------------------------------------------------------------------------------|---------------------|----------------------------------|---------------------------------------------------|-------------|-------------------------------|-----------------------------|---------------|-----------------| | [Table_Main[ 昭 TIna | 衍 fbole] 新 _T 药 itle] (603127) | | | [Table_industryInfo] | | \n[ 评 Tab 级 le_ | ： Inv ...

年04月02日 公司点评 公 司 研 究 昭衍新药(603127) 目标价: 昨收盘:18.08 ◼ 走势比较 ◼ 股票数据 相关研究报告 证券分析师：周豫 电话： E-MAIL：zhouyua@tpyzq.com 3 月 29 日，公司发布 2023 年年报，2023 年实现营业收入 23.76 亿 元，同比增长 4.78%，归母净利润为 3.97 亿元，同比下滑 63.04%，扣非 后归母净利为 3.38 亿元，同比下滑 66.89%。 点评： 全年收入稳定增长，海外业务增速亮眼。单季度来看，2023Q4 实现 营业收入 7.89 亿元，同比下滑 20.39%，归母净利润为 0.69 亿元，同比 下滑 84.31%，扣非后归母净利为 0.26 亿元，同比下滑 93.61%。全年来 看，公司 2023 年收入同比增长 4.78%，利润同比下滑 63.04%，主要原因 是生物资产公允价值变动带来损失 2.67 亿元（2022 年为收益 3.33 亿元， 我们预计主要和猴价波动有关）以及资金管理收益为 1.31 亿元。若剔除 上述影响因素后，扣非后归母净利为 4.73 亿元，同比下滑 17.90%。分地 区来看 ...

昭衍新药（603127.SH）/医药生物 证券研究报告/公司点评 2024 年 04 月 07 日 | --- | --- | --- | --- | --- | --- | --- | --- | |-----------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ...

二、 回购股份的进展情况 证券代码：603127 证券简称：昭衍新药 公告编号：2024-018 北京昭衍新药研究中心股份有限公司 关于以集中竞价交易方式回购公司 A 股股份的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： | 回购方案首次披露日 | 2024/3/29 | | --- | --- | | 回购方案实施期限 | 待董事会审议通过后 12 个月 | | 预计回购金额 | 亿元 0.5 亿元~1 | | 回购用途 | 用于员工持股计划或股权激励 | | 累计已回购股数 | 0 股 | | 累计已回购股数占总股本比例 | 0% | | 累计已回购金额 | 0 亿元 | | 实际回购价格区间 | -元/股 | 一、 回购股份的基本情况 北京昭衍新药研究中心股份有限公司（以下简称"公司"）于 2024 年 3 月 28 日召开第四届董事会第七次会议，审议通过了《昭衍新药关于以集中竞价交易方 式回购公司 A 股股份的议案》，同意公司以自有资金通过上海证券交易所交易系 统以集中竞价交易方式回购公司已 ...